Design Therapeutics (DSGN) said Thursday its experimental DT-168 eye drops to potentially treat Fuchs endothelial corneal dystrophy were well-tolerated in a phase 1 trial.
The company said no serious side effects nor eye-related issues were reported. No treatment was discontinued due to adverse side effects, Design added.
The company said it expects to begin a phase 2 biomarker trial in patients with Fuchs endothelial corneal dystrophy in H2, with results anticipated in 2026.
The study will enroll FECD patients scheduled for corneal transplant surgery, the company added.
Shares of the company were down 3.3% in recent trading.
Price: 4.70, Change: -0.16, Percent Change: -3.29
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.